Congratulations to GenomiCare’ Scientific Advisory Board member Dr. Chen Lieping， for being elected as new member of the National Academy of Sciences (NAS)。
genomicare.us/about/news/9
# NationalAcademyofSciences #
English
GenomiCare
14 posts
GenomiCare
@GenomiCare
GenomiCare provides data-driven drug development services to biopharma and pharmaceutical companies.
Katılım Temmuz 2020
73 Takip Edilen14 Takipçiler
GenomiCare Is on List of 2020 Deloitte China Technology Fast 50 & China Rising Star
genomicare.us/about/news/7
English
GenomiCare Wins Two Awards at 2020 International Sci-Tech Innovation Festival
GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine.
genomicare.us/about/news/6
English
sharing how data-driven real-world clinical research solutions can provide biopharmaceutical companies with powerful data mining capabilities and assist in the development and commercialization of oncology drugs .
English
Dr. Xu Qiang, the founder, president and CEO of GenomiCare, attended the 2020 China BioMed Innovation and Investment Conference (CBIIC). At the meeting, he delivered a speech on "Data-driven algorithm accelerates new drug development",
English
aiming to speed up FDA/NMPA approvals by providing customized drug development strategies that help pharmaceuticals to better cope with unmet medical needs.
English
At the meeting, Dr. Xu Qiang demonstrated the extensive applications of the Clinical Intelligence Analysis Platform (CIAP) across the overall drug development course,
GenomiCare@GenomiCare
Dr. Xu Qiang, founder, president and CEO of Genomicare, was invited to report “ Data-driven algorithm accelerates new drug development " at 2020 DIA Digital Technology in Clinical Trials Conference"at 4 Sep, Nanjing.
English
can support cancer translational research and tumor drug clinical development, by illustrating an example of the application of CIAP and data driven algorithm in the real world data setting.
English
In his speech, Dr. Xu Qiang emphasized how real-world oncology clinical-genomic data combined with GenomiCare’s proprietary artificial intelligence data-driven algorithm and Clinical Intelligence Analysis Platform (CIAP)
GenomiCare@GenomiCare
Dr. Xu Qiang, founder, president and CEO of Genomicare, will give an oral report named "Data-driven algorithm accelerates new drug development”at the "Cancer Diagnosis and Treatment Black Technology Conference" on September 2nd.
English
GenomiCare retweetledi
Patients with chronic coronary disease were randomized to daily colchicine or placebo. Incidence of the composite endpoint of cardiovascular death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine. #ESCCongress
English
Dr. Xu Qiang, founder, president and CEO of Genomicare, was invited to report “ Data-driven algorithm accelerates new drug development " at 2020 DIA Digital Technology in Clinical Trials Conference"at 4 Sep, Nanjing.
English
GenomiCare and Laekna Therapeutics today announced an expanded strategic collaboration, focusing on indications expansion and combination therapy for cancer patients.
English
Dr. Xu Qiang, founder, president and CEO of Genomicare, will give an oral report named "Data-driven algorithm accelerates new drug development”at the "Cancer Diagnosis and Treatment Black Technology Conference" on September 2nd.
English
GenomiCare Partners with AWS on HIPAA Eligible Services for Higher Data Security genomicare.us/about/news/1
English